<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gene test interpretation: &lt;i&gt;RPE65&lt;/i&gt;
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gene test interpretation:
       <i>
        RPE65
       </i>
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gene test interpretation:
        <i>
         RPE65
        </i>
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Seema Garg, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Matthew F Gardiner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jane Givens, MD, MSCE
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 14, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1602215524">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This monograph summarizes the interpretation of germline genetic testing of
         <em>
          RPE65
         </em>
         , a gene associated with autosomal recessive retinitis pigmentosa-20 (RP20) and Leber congenital amaurosis (LCA), a form of retinitis pigmentosa present at birth. Evaluation and management of retinitis pigmentosa are discussed in detail separately [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2106994720">
         <span class="h2">
          <i>
           RPE65
          </i>
          gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          RPE65
         </em>
         gene, located on chromosome 1p31, encodes for a protein that is an enzyme critical for the normal functioning of the visual cycle. This protein, RPE65, is an all-trans-retinyl ester isomerase expressed in the retinal pigment epithelium (RPE). It is responsible for the functioning of the rods and cones (photoreceptors in the retina) because of its essential role in the biochemical recycling of chromophore in the visual cycle, which results in the transmission of electrical signals to the brain. Pathogenic variants in the RPE gene lead to reduced or absent levels of
         <em>
          RPE65.
         </em>
         Without this important enzyme, the biochemical visual cycle is blocked, resulting in impaired vision. As RPE65 is inherited in an autosomal recessive pattern, affected individuals are homozygous or compound heterozygous for a pathogenic variant in the
         <em>
          RPE65
         </em>
         gene.
        </p>
        <p class="headingAnchor" id="H1012644071">
         <span class="h2">
          How to read the report
         </span>
         <span class="headingEndMark">
          —
         </span>
         Confirm that the testing was performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (or other nationally certified laboratory); if this is not the case, testing should be repeated in a certified laboratory. These and other caveats are summarized in the checklist  (
         <a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H679480192">
         <span class="h2">
          Disease association
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retinitis pigmentosa comprises a complex group of inherited retinal dystrophies characterized by progressive degeneration, primarily affecting the photoreceptors and RPE, the supportive layer for the photoreceptors. Retinitis pigmentosa may occur alone or as part of a syndrome and may be inherited as a dominant, recessive, or X-linked trait or occur sporadically. The same pathogenic variant may cause different symptoms in different individuals, and the same syndrome may be caused by pathogenic variants in other genes. The clinical manifestations of retinitis pigmentosa include reduction in light sensitivity (night blindness), loss of peripheral vision from progressive loss of rods, and variable decrease in central vision due to loss of cones, cataracts, or macular edema.
        </p>
        <p>
         The diagnosis of retinitis pigmentosa is made by a combination of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of nyctalopia (difficulty adapting to the dark) and gradual peripheral vision loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retinal fundus examination findings of "waxy pallor" of the optic nerve, retinal arterial attenuation, and pigmentary changes in the peripheral retina.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ancillary testing results (attenuation of the rod response, and later cone response, on the full-field electroretinogram [ERG], constriction of the visual field on Goldmann perimetry, and abnormal dark adaptometry).
        </p>
        <p>
        </p>
        <p>
         As treatment is available for confirmed biallelic
         <em>
          RPE65
         </em>
         mutation-associated retinal dystrophy, it is important that genetic testing be offered for patients with LCA and early-onset retinitis pigmentosa. If genetic testing confirms that the patient does NOT have the
         <em>
          RPE65
         </em>
         mutation in both alleles, the molecular diagnosis may help determine eligibility for inclusion into ongoing retinitis pigmentosa clinical trials.
        </p>
        <p class="headingAnchor" id="H3549934746">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2094654086">
         <span class="h2">
          Biallelic pathogenic variant in
          <i>
           RPE65
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retinal gene therapy (voretigene neparvovec-rzyl) was US Food and Drug Administration (FDA)-approved in 2017 for
         <em>
          RPE65
         </em>
         -associated inherited retinal disease. Genetic testing must confirm the
         <em>
          RPE65
         </em>
         mutation in both genes and there must be viable retinal cells, as determined by a health care professional. The treatment is administered in the operating room, via a subretinal injection. Phase 3 clinical trial results showed improvements in ambulatory navigation, light sensitivity, and visual fields up to four years after a single injection [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Experimental approaches to treatment for retinitis pigmentosa include stem cell transplantation, and electronic retinal prostheses. Patients with retinitis pigmentosa and macular edema are treated with an oral or topical carbonic anhydrase inhibitor. In patients with retinitis pigmentosa and cataracts, cataract extraction may improve central vision. However, patients must be aware that there will likely be no improvement in their visual field and no impact on progression of disease. (See
         <a class="local">
          'Locating an expert'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6911.html" rel="external">
          "Retinitis pigmentosa: Treatment", section on 'Gene therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4272103168">
         <span class="h2">
          VUS or negative genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of individuals with negative genetic testing depends on the likelihood of disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Negative genetic testing for a known familial pathogenic variant
         </strong>
         – Negative testing for a pathogenic variant of
         <em>
          RPE65
         </em>
         previously identified in other family members very likely excludes retinitis pigmentosa in the patient undergoing testing, with caveats noted above. (See
         <a class="local">
          'How to read the report'
         </a>
         above and
         <a class="local">
          'Disease association'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Negative genetic testing if familial
         </strong>
         <strong>
          <em>
          </em>
         </strong>
         <strong>
          variant unknown
         </strong>
         –
         <em>
         </em>
         If retinitis pigmentosa is suspected based on personal or family history and a familial variant has
         <strong>
          not
         </strong>
         been characterized, then negative testing of
         <em>
          RPE65
         </em>
         cannot be used to exclude the disorder. Consultation with a genetics expert is advised to determine the next steps, which may include panel testing for other retinitis pigmentosa genes or more extensive testing of
         <em>
          RPE65
         </em>
         . Genetic variants in the
         <em>
          RPE65
         </em>
         gene are responsible for a small percentage of individuals with retinitis pigmentosa. (See
         <a class="medical medical_review" href="/z/d/html/6905.html" rel="external">
          "Retinitis pigmentosa: Clinical presentation and diagnosis", section on 'Genetics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Variant of uncertain significance (VUS)
         </strong>
         – Often, the genetic testing results in a VUS, meaning the pathogenicity of the variant has not been determined. Individuals with a VUS may benefit from consultation with an expert in retinitis pigmentosa or a genetics expert to assist in determining what is known about the variant. (See
         <a class="local">
          'Locating an expert'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2660643988">
         <span class="h1">
          CONSIDERATIONS FOR FAMILY MEMBERS
         </span>
        </p>
        <p class="headingAnchor" id="H686719922">
         <span class="h2">
          Preconception counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          RPE65
         </em>
         -associated retinitis pigmentosa is inherited in an autosomal recessive pattern. Therefore, the children of an individual who carries an
         <em>
          RPE65
         </em>
         mutation will be obligate carriers if their parent has two pathogenic or likely pathogenic
         <em>
          RPE65
         </em>
         variants. They could be affected with retinitis pigmentosa if their other parent is also a carrier of a disease variant.
        </p>
        <p class="headingAnchor" id="H2833089393">
         <span class="h2">
          At-risk relatives
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who test positive for a pathogenic variant or likely pathogenic variant should inform their at-risk relatives about the importance of genetic counseling and possible testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Siblings of a patient with biallelic germline
         <em>
          RPE65
         </em>
         variants have a 25 percent chance of having inherited both
         <em>
          RPE65
         </em>
         variants and a 50 percent chance of being carriers (heterozygotes) of a single
         <em>
          RPE65
         </em>
         variant if they have the same biological parents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reproductive counseling should be provided to discuss reproductive options. Each child has a 25 percent risk of being affected if both parents are carriers. Some may elect to conceive using donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT). (See
         <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">
          "In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7423.html" rel="external">
          "Donor insemination"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">
          "Preimplantation genetic testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3733250902">
         <span class="h1">
          RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H3152925116">
         <span class="h2">
          Information about
          <i>
           RPE65
          </i>
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          UpToDate topics
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Genetics – (See
         <a class="medical medical_review" href="/z/d/html/6905.html" rel="external">
          "Retinitis pigmentosa: Clinical presentation and diagnosis", section on 'Genetics'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinical features and diagnosis – (See
         <a class="medical medical_review" href="/z/d/html/6905.html" rel="external">
          "Retinitis pigmentosa: Clinical presentation and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment – (See
         <a class="medical medical_review" href="/z/d/html/6911.html" rel="external">
          "Retinitis pigmentosa: Treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Retinitis pigmentosa resources
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Foundation for Fighting Blindness (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fightingblindness.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5eolXhZs53tE19HLEURsoQvzsLjwHwDKTuftOSdkfO39&amp;TOPIC_ID=139282" target="_blank">
          FFB
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lighthouse Guild –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Flighthouseguild.org%2Fretinitis-pigmentosa%2F&amp;token=WhUQIRHs99TZxZpKH9Zs5dYuPtmodap711PtvCA8ZPheKqqMdvI%2FgL2MMvoqcdPoOIFQMLhEYmgd7m4ZdD0egQ%3D%3D&amp;TOPIC_ID=139282" target="_blank">
          Retinitis pigmentosa
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         American Academy of Ophthalmology –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aao.org%2Feye-health%2Fdiseases%2Fwhat-is-retinitis-pigmentosa&amp;token=s8vbWinHDHJN1LSlzxFPc7rbK53BkQJWmvZ9NOKlJJ9jj2VpmOoq8pIHeVqrzmUvtZZFehGIhRXsixDxjhDearOkP5YLB%2B%2BtpeL2oqo005A%3D&amp;TOPIC_ID=139282" target="_blank">
          Eye Smart: Retinitis Pigmentosa Treatment
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         National Organization for Rare Disorders (NORD) –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Frarediseases.org%2Frare-diseases%2Fretinitis-pigmentosa%2F&amp;token=9E9IX7kiH9qRiTPgEvfhBXfzSfVr6Je40Jo5pwBzJ8XPRzGHQOJlLGAZ08h2LAmlc%2FLp96xS0aJaVJAlo4ftqQ%3D%3D&amp;TOPIC_ID=139282" target="_blank">
          Retinitis pigmentosa
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fretina-international.org%2F&amp;token=y78QdDnF6ndDlR0qZzkg0xaJATyYsFwktJL0VcbR9vxsysE1k4PmCBoL%2Fg59uYHs&amp;TOPIC_ID=139282" target="_blank">
          RI
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1681235272">
         <span class="h2">
          Locating an expert
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical geneticists
         </strong>
         – American College of Medical Genetics and Genomics (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=139282" target="_blank">
          ACMG
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic counselors
         </strong>
         – National Society of Genetic Counselors (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F%3Freload%3Dtimezone&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflzQ%2BZ4POBsSFXQiuwJDn5pefBPIAES8nVSzeVi4Tr3mXQ%3D%3D&amp;TOPIC_ID=139282" target="_blank">
          NSGC
         </a>
         ). Genetic testing laboratories may also provide online or telephone access to a genetic counselor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          National Institutes of Health (NIH) Cancer Genetics
         </strong>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=139282" target="_blank">
          Services Directory
         </a>
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maguire AM, Russell S, Chung DC, et al. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years. Ophthalmology 2021; 128:1460.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 139282 Version 1.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33798654" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
